EGFR and neoplasm: For example, 80% of metastatic lung cancer patients with EGFR-activating mutations (EGFRmut) initially respond to osimertinib, a third-generation EGFR-targeting drug; yet, almost all experience tumor progression within 2 years, with a median duration of response of 17 months (2).